Forward Pharma files Form F-1 registration statement for initial public offering of shares

Forward Pharma A/S, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, today announced that it has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not yet been determined. Forward Pharma intends to list its ordinary shares on the NASDAQ under the ticker symbol "FWP."

Leerink Partners LLC is acting as sole book running manager and as a representative of the underwriters for the proposed offering. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus related to the offering may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by email at [email protected], or by calling (800) 808-7525.